Skip to content

Neoantigens in cancer immunotherapy

Ton N. Schumacher, Robert D. Schreiber

Science · 2015 · 4,848 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69–74. https://doi.org/10.1126/science.aaa4971

In text: (Schumacher & Schreiber, 2015)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

The clinical relevance of T cells in the control of a diverse set of human cancers is now beyond doubt. However, the nature of the antigens that allow the immune system to distinguish cancer cells from noncancer cells has long remained obscure. Recent technological innovations have made it possible to dissect the immune response to patient-specific neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that recognition of such neoantigens is a major factor in the activity of clinical immunotherapies. These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.

  1. Integrated analysis of multimodal single-cell data2021
  2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
  3. Control of Regulatory T Cell Development by the Transcription Factor Foxp32003
  4. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer2012
  5. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.1986

Metadata from OpenAlex (CC0). Citations are generated from the published record.